Clearbridge LLC boosted its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 8.7% during the 4th quarter, HoldingsChannel reports. The fund owned 119,295 shares of the biopharmaceutical company’s stock after acquiring an additional 9,545 shares during the quarter. Alexion Pharmaceuticals comprises 3.5% of Clearbridge LLC’s investment portfolio, making the stock its 5th largest position. Clearbridge LLC’s holdings in Alexion Pharmaceuticals were worth $11,615,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently bought and sold shares of the company. FMR LLC lifted its position in Alexion Pharmaceuticals by 8.1% during the 3rd quarter. FMR LLC now owns 21,096,993 shares of the biopharmaceutical company’s stock worth $2,932,693,000 after buying an additional 1,581,376 shares in the last quarter. BlackRock Inc. lifted its position in Alexion Pharmaceuticals by 0.3% during the 3rd quarter. BlackRock Inc. now owns 16,302,528 shares of the biopharmaceutical company’s stock worth $2,266,214,000 after buying an additional 41,943 shares in the last quarter. Vanguard Group Inc. lifted its position in Alexion Pharmaceuticals by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 15,811,291 shares of the biopharmaceutical company’s stock worth $2,197,928,000 after buying an additional 192,857 shares in the last quarter. Vanguard Group Inc lifted its position in Alexion Pharmaceuticals by 1.2% during the 3rd quarter. Vanguard Group Inc now owns 15,811,291 shares of the biopharmaceutical company’s stock worth $2,197,928,000 after buying an additional 192,857 shares in the last quarter. Finally, Jennison Associates LLC lifted its position in Alexion Pharmaceuticals by 1.2% during the 4th quarter. Jennison Associates LLC now owns 8,728,912 shares of the biopharmaceutical company’s stock worth $849,847,000 after buying an additional 101,376 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.
In related news, CAO Daniel Bazarko sold 2,000 shares of the company’s stock in a transaction dated Thursday, February 14th. The shares were sold at an average price of $126.00, for a total value of $252,000.00. Following the transaction, the chief accounting officer now owns 5,020 shares in the company, valued at approximately $632,520. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Ludwig Hantson sold 3,244 shares of the company’s stock in a transaction dated Monday, December 31st. The shares were sold at an average price of $95.85, for a total transaction of $310,937.40. Following the completion of the transaction, the chief executive officer now owns 150,696 shares in the company, valued at approximately $14,444,211.60. The disclosure for this sale can be found here. Insiders have sold a total of 8,488 shares of company stock worth $873,875 over the last 90 days. 4.35% of the stock is owned by company insiders.
Alexion Pharmaceuticals stock opened at $134.88 on Friday. The stock has a market cap of $30.33 billion, a PE ratio of 19.02, a PEG ratio of 1.00 and a beta of 1.55. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $92.56 and a fifty-two week high of $140.77. The company has a current ratio of 2.88, a quick ratio of 2.48 and a debt-to-equity ratio of 0.31.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $2.14 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.54. The company had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.06 billion. Alexion Pharmaceuticals had a net margin of 1.88% and a return on equity of 18.15%. Alexion Pharmaceuticals’s revenue for the quarter was up 24.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.48 EPS. Research analysts expect that Alexion Pharmaceuticals, Inc. will post 8.51 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/4222904/alexion-pharmaceuticals-inc-alxn-shares-bought-by-clearbridge-llc.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
See Also: Why Net Income is Important to Investors
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.